{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:36:40Z","timestamp":1789706200926,"version":"4.0.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,3,22]],"date-time":"2013-03-22T00:00:00Z","timestamp":1363910400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1471-2407-13-140","type":"journal-article","created":{"date-parts":[[2013,3,21]],"date-time":"2013-03-21T21:14:16Z","timestamp":1363900456000},"source":"Crossref","is-referenced-by-count":13,"title":["TRAIL and proteasome inhibitors combination induces a robust apoptosis in human malignant pleural mesothelioma cells through Mcl-1 and Akt protein cleavages"],"prefix":"10.1186","volume":"13","author":[{"given":"Bao-Zhu","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yon","family":"Rojanasakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven H","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,3,22]]},"reference":[{"key":"3884_CR1","first-page":"313","volume":"8","author":"KH Antman","year":"1981","unstructured":"Antman KH: Clinical presentation and natural history of benign and malignant mesothelioma. Semin Oncol. 1981, 8: 313-320.","journal-title":"Semin Oncol"},{"key":"3884_CR2","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1093\/oxfordjournals.aje.a009093","volume":"145","author":"B Price","year":"1997","unstructured":"Price B: Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol. 1997, 145: 211-218. 10.1093\/oxfordjournals.aje.a009093.","journal-title":"Am J Epidemiol"},{"key":"3884_CR3","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s11912-005-0048-3","volume":"7","author":"RK Goudar","year":"2005","unstructured":"Goudar RK: New therapeutic options for mesothelioma. Curr Oncol Rep. 2005, 7: 260-265. 10.1007\/s11912-005-0048-3.","journal-title":"Curr Oncol Rep"},{"key":"3884_CR4","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.hoc.2005.09.010","volume":"19","author":"LM Krug","year":"2005","unstructured":"Krug LM: An overview of chemotherapy for mesothelioma. Hematol Oncol Clin North Am. 2005, 19: 1117-1136. 10.1016\/j.hoc.2005.09.010. vii","journal-title":"Hematol Oncol Clin North Am"},{"key":"3884_CR5","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003, 21: 2636-2644. 10.1200\/JCO.2003.11.136.","journal-title":"J Clin Oncol"},{"key":"3884_CR6","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1158\/1078-0432.CCR-04-1940","volume":"11","author":"R Govindan","year":"2005","unstructured":"Govindan R, Kratzke RA, Herndon JE, Niehans GA, Vollmer R, Watson D, Green MR, Kindler HL: Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res. 2005, 11: 2300-2304. 10.1158\/1078-0432.CCR-04-1940.","journal-title":"Clin Cancer Res"},{"key":"3884_CR7","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1093\/annonc\/mdm093","volume":"18","author":"W Weder","year":"2007","unstructured":"Weder W, Stahel RA, Bernhard J, Bodis S, Vogt P, Ballabeni P, Lardinois D, Betticher D, Schmid R, Stupp R: Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol. 2007, 18: 1196-1202. 10.1093\/annonc\/mdm093. Epub 2007 Apr 1111","journal-title":"Ann Oncol"},{"key":"3884_CR8","first-page":"75","volume":"74","author":"S Bolukbas","year":"2009","unstructured":"Bolukbas S, Manegold C, Eberlein M, Bergmann T, Fisseler-Eckhoff A, Schirren J: Survival after trimodality therapy for malignant pleural mesothelioma: radical pleurectomy, chemotherapy with Cisplatin\/Permetrexed and radiotherapy. Lung Cancer. 2009, 74: 75-85.","journal-title":"Lung Cancer"},{"key":"3884_CR9","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/S0962-8924(01)82111-5","volume":"11","author":"G Makin","year":"2001","unstructured":"Makin G, Dive C: Apoptosis and cancer chemotherapy. Trends Cell Biol. 2001, 11: S22-S26.","journal-title":"Trends Cell Biol"},{"key":"3884_CR10","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1101\/gad.12.11.1551","volume":"12","author":"V Cryns","year":"1998","unstructured":"Cryns V, Yuan J: Proteases to die for. Genes Dev. 1998, 12: 1551-1570. 10.1101\/gad.12.11.1551.","journal-title":"Genes Dev"},{"key":"3884_CR11","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.ccr.2006.05.004","volume":"9","author":"DR Green","year":"2006","unstructured":"Green DR: At the gates of death. Cancer Cell. 2006, 9: 328-330. 10.1016\/j.ccr.2006.05.004.","journal-title":"Cancer Cell"},{"key":"3884_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1146\/annurev.biochem.73.011303.073706","volume":"73","author":"X Jiang","year":"2004","unstructured":"Jiang X, Wang X: Cytochrome C-mediated apoptosis. Annu Rev Biochem. 2004, 73: 87-106. 10.1146\/annurev.biochem.73.011303.073706.","journal-title":"Annu Rev Biochem"},{"key":"3884_CR13","doi-asserted-by":"publisher","first-page":"8590","DOI":"10.1038\/sj.onc.1207102","volume":"22","author":"S Cory","year":"2003","unstructured":"Cory S, Huang DC, Adams JM: The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene. 2003, 22: 8590-8607. 10.1038\/sj.onc.1207102.","journal-title":"Oncogene"},{"key":"3884_CR14","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1126\/science.296.5573.1655","volume":"296","author":"LC Cantley","year":"2002","unstructured":"Cantley LC: The phosphoinositide 3-kinase pathway. Science. 2002, 296: 1655-1657. 10.1126\/science.296.5573.1655.","journal-title":"Science"},{"key":"3884_CR15","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrc839","volume":"2","author":"I Vivanco","year":"2002","unstructured":"Vivanco I, Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002, 2: 489-501. 10.1038\/nrc839.","journal-title":"Nat Rev Cancer"},{"key":"3884_CR16","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.ejcts.2007.09.045","volume":"33","author":"I Opitz","year":"2008","unstructured":"Opitz I, Soltermann A, Abaecherli M, Hinterberger M, Probst-Hensch N, Stahel R, Moch H, Weder W: PTEN expression is a strong predictor of survival in mesothelioma patients. Eur J Cardiothorac Surg. 2008, 33: 502-506. 10.1016\/j.ejcts.2007.09.045.","journal-title":"Eur J Cardiothorac Surg"},{"key":"3884_CR17","doi-asserted-by":"publisher","first-page":"4082","DOI":"10.1158\/0008-5472.CAN-04-0486","volume":"64","author":"E Aldieri","year":"2004","unstructured":"Aldieri E, Orecchia S, Ghigo D, Bergandi L, Riganti C, Fubini B, Betta PG, Bosia A: Simian virus 40 infection down-regulates the expression of nitric oxide synthase in human mesothelial cells. Cancer Res. 2004, 64: 4082-4084. 10.1158\/0008-5472.CAN-04-0486.","journal-title":"Cancer Res"},{"key":"3884_CR18","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.1038\/sj.onc.1206552","volume":"22","author":"M Carbone","year":"2003","unstructured":"Carbone M, Pass HI, Miele L, Bocchetta M: New developments about the association of SV40 with human mesothelioma. Oncogene. 2003, 22: 5173-5180. 10.1038\/sj.onc.1206552.","journal-title":"Oncogene"},{"key":"3884_CR19","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/S0022-5223(98)00438-3","volume":"116","author":"HI Pass","year":"1998","unstructured":"Pass HI, Donington JS, Wu P, Rizzo P, Nishimura M, Kennedy R, Carbone M: Human mesotheliomas contain the simian virus-40 regulatory region and large tumor antigen DNA sequences. J Thorac Cardiovasc Surg. 1998, 116: 854-859. 10.1016\/S0022-5223(98)00438-3.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"3884_CR20","doi-asserted-by":"publisher","first-page":"5256","DOI":"10.1158\/0008-5472.CAN-05-0127","volume":"65","author":"P Cacciotti","year":"2005","unstructured":"Cacciotti P, Barbone D, Porta C, Altomare DA, Testa JR, Mutti L, Gaudino G: SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure. Cancer Res. 2005, 65: 5256-5262. 10.1158\/0008-5472.CAN-05-0127.","journal-title":"Cancer Res"},{"key":"3884_CR21","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1535-6108(04)00120-5","volume":"5","author":"J Adams","year":"2004","unstructured":"Adams J: The development of proteasome inhibitors as anticancer drugs. Cancer Cell. 2004, 5: 417-421. 10.1016\/S1535-6108(04)00120-5.","journal-title":"Cancer Cell"},{"key":"3884_CR22","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1038\/sj.cdd.4401729","volume":"12","author":"CJ Henderson","year":"2005","unstructured":"Henderson CJ, Aleo E, Fontanini A, Maestro R, Paroni G, Brancolini C: Caspase activation and apoptosis in response to proteasome inhibitors. Cell Death Differ. 2005, 12: 1240-1254. 10.1038\/sj.cdd.4401729.","journal-title":"Cell Death Differ"},{"key":"3884_CR23","doi-asserted-by":"publisher","first-page":"3775","DOI":"10.1038\/onc.2009.240","volume":"28","author":"B Yuan","year":"2009","unstructured":"Yuan B, Chapman J, Reynolds SH: Proteasome inhibitors induce apoptosis in human lung cancer cells through a positive feedback mechanism and the subsequent Mcl-1 protein cleavage. Oncogene. 2009, 28: 3775-3786. 10.1038\/onc.2009.240.","journal-title":"Oncogene"},{"key":"3884_CR24","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1593\/tlo.08133","volume":"1","author":"B-Z Yuan","year":"2008","unstructured":"Yuan B-Z, Chapman JA, Reynolds SH: Proteasome inhibitor MG132 induces apoptosis and inhibits invasion of human malignant pleural mesothelioma cells. Translational Oncology. 2008, 1: 129-140.","journal-title":"Translational Oncology"},{"key":"3884_CR25","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.4161\/cc.7.11.5975","volume":"7","author":"N Finnberg","year":"2008","unstructured":"Finnberg N, El-Deiry WS: TRAIL death receptors as tumor suppressors and drug targets. Cell Cycle. 2008, 7: 1525-1528. 10.4161\/cc.7.11.5975.","journal-title":"Cell Cycle"},{"key":"3884_CR26","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/nrc2465","volume":"8","author":"RW Johnstone","year":"2008","unstructured":"Johnstone RW, Frew AJ, Smyth MJ: The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer. 2008, 8: 782-798. 10.1038\/nrc2465.","journal-title":"Nat Rev Cancer"},{"key":"3884_CR27","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s00262-005-0676-3","volume":"55","author":"TJ Sayers","year":"2006","unstructured":"Sayers TJ, Murphy WJ: Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L\/TRAIL) for cancer therapy. Cancer Immunol Immunother. 2006, 55: 76-84. 10.1007\/s00262-005-0676-3.","journal-title":"Cancer Immunol Immunother"},{"key":"3884_CR28","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1006\/bbrc.1999.0712","volume":"260","author":"T Das","year":"1999","unstructured":"Das T, Sa G, Sinha P, Ray PK: Induction of cell proliferation and apoptosis: dependence on the dose of the inducer. Biochem Biophys Res Commun. 1999, 260: 105-110. 10.1006\/bbrc.1999.0712.","journal-title":"Biochem Biophys Res Commun"},{"key":"3884_CR29","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/sj.onc.1201947","volume":"17","author":"A Bellacosa","year":"1998","unstructured":"Bellacosa A, Chan TO, Ahmed NN, Datta K, Malstrom S, Stokoe D, McCormick F, Feng J, Tsichlis P: Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene. 1998, 17: 313-325. 10.1038\/sj.onc.1201947.","journal-title":"Oncogene"},{"key":"3884_CR30","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1038\/sj.onc.1207291","volume":"23","author":"BZ Yuan","year":"2004","unstructured":"Yuan BZ, Jefferson AM, Baldwin KT, Thorgeirsson SS, Popescu NC, Reynolds SH: DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas. Oncogene. 2004, 23: 1405-1411. 10.1038\/sj.onc.1207291.","journal-title":"Oncogene"},{"key":"3884_CR31","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.1016\/j.yexcr.2007.08.009","volume":"313","author":"BZ Yuan","year":"2007","unstructured":"Yuan BZ, Jefferson AM, Millecchia L, Popescu NC, Reynolds SH: Morphological changes and nuclear translocation of DLC1 tumor suppressor protein precede apoptosis in human non-small cell lung carcinoma cells. Exp Cell Res. 2007, 313: 3868-3880. 10.1016\/j.yexcr.2007.08.009.","journal-title":"Exp Cell Res"},{"key":"3884_CR32","first-page":"945","volume":"8","author":"R Buettner","year":"2002","unstructured":"Buettner R, Mora LB, Jove R: Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res. 2002, 8: 945-954.","journal-title":"Clin Cancer Res"},{"key":"3884_CR33","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S0163-7258(98)00071-0","volume":"82","author":"I Galetic","year":"1999","unstructured":"Galetic I, Andjelkovic M, Meier R, Brodbeck D, Park J, Hemmings BA: Mechanism of protein kinase B activation by insulin\/insulin-like growth factor-1 revealed by specific inhibitors of phosphoinositide 3-kinase\u2013significance for diabetes and cancer. Pharmacol Ther. 1999, 82: 409-425. 10.1016\/S0163-7258(98)00071-0.","journal-title":"Pharmacol Ther"},{"key":"3884_CR34","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1101\/gad.1093903","volume":"17","author":"D Nijhawan","year":"2003","unstructured":"Nijhawan D, Fang M, Traer E, Zhong Q, Gao W, Du F, Wang X: Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev. 2003, 17: 1475-1486. 10.1101\/gad.1093903.","journal-title":"Genes Dev"},{"key":"3884_CR35","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.cell.2005.06.009","volume":"121","author":"Q Zhong","year":"2005","unstructured":"Zhong Q, Gao W, Du F, Wang X: Mule\/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell. 2005, 121: 1085-1095. 10.1016\/j.cell.2005.06.009.","journal-title":"Cell"},{"key":"3884_CR36","doi-asserted-by":"publisher","first-page":"10491","DOI":"10.1074\/jbc.M412819200","volume":"280","author":"C Weng","year":"2005","unstructured":"Weng C, Li Y, Xu D, Shi Y, Tang H: Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells. J Biol Chem. 2005, 280: 10491-10500. 10.1074\/jbc.M412819200.","journal-title":"J Biol Chem"},{"key":"3884_CR37","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.drup.2007.11.003","volume":"11","author":"J LoPiccolo","year":"2008","unstructured":"LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA: Targeting the PI3K\/Akt\/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat. 2008, 11: 32-50. 10.1016\/j.drup.2007.11.003.","journal-title":"Drug Resist Updat"},{"key":"3884_CR38","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1101\/gad.1304105","volume":"19","author":"SN Willis","year":"2005","unstructured":"Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI, Adams JM, Huang DC: Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 2005, 19: 1294-1305. 10.1101\/gad.1304105.","journal-title":"Genes Dev"},{"key":"3884_CR39","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/36442","volume":"390","author":"TF Franke","year":"1997","unstructured":"Franke TF, Cantley LC: Apoptosis. A Bad kinase makes good. Nature. 1997, 390: 116-117. 10.1038\/36442.","journal-title":"Nature"},{"key":"3884_CR40","doi-asserted-by":"publisher","first-page":"42457","DOI":"10.1074\/jbc.M303376200","volume":"278","author":"YY He","year":"2003","unstructured":"He YY, Huang JL, Gentry JB: Chignell. Epidermal growth factor receptor down-regulation induced by UVA in human keratinocytes does not require the receptor kinase activity. J Biol Chem. 2003, 278: 42457-42465. 10.1074\/jbc.M303376200.","journal-title":"J Biol Chem"},{"key":"3884_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0036856","volume":"7","author":"G Pinton","year":"2012","unstructured":"Pinton G, Manente AG, Angeli G, Mutti L, Moro L: Perifosine as a potential novel anti-cancer agent inhibits EGFR\/MET-AKT axix in malignant pleural mesothelioma. PloS One. 2012, 7: 1-7.","journal-title":"PloS One"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-140.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-13-140\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-140","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,7,12]],"date-time":"2016-07-12T15:38:24Z","timestamp":1468337904000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-13-140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,22]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["3884"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-13-140","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,22]]},"article-number":"140"}}